Therapeutic applications of TRAIL receptor agonists in cancer and beyond

Pharmacology & Therapeutics
Gustavo P Amarante-Mendes, T S Griffith

Abstract

TRAIL/Apo-2L is a member of the TNF superfamily first described as an apoptosis-inducing cytokine in 1995. Similar to TNF and Fas ligand, TRAIL induces apoptosis in caspase-dependent manner following TRAIL death receptor trimerization. Because tumor cells were shown to be particularly sensitive to this cytokine while normal cells/tissues proved to be resistant along with being able to synthesize and release TRAIL, it was rapidly appreciated that TRAIL likely served as one of our major physiologic weapons against cancer. In line with this, a number of research laboratories and pharmaceutical companies have attempted to exploit the ability of TRAIL to kill cancer cells by developing recombinant forms of TRAIL or TRAIL receptor agonists (e.g., receptor-specific mAb) for therapeutic purposes. In this review article we will describe the biochemical pathways used by TRAIL to induce different cell death programs. We will also summarize the clinical trials related to this pathway and discuss possible novel uses of TRAIL-related therapies. In recent years, the physiological importance of TRAIL has expanded beyond being a tumoricidal molecule to one critical for a number of clinical settings - ranging from infectious disease and autoimmu...Continue Reading

References

Sep 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·E A CarswellB Williamson
Jan 1, 1988·Immunology Today·A Cerami, B Beutler
Jan 1, 1987·Cancer Chemotherapy and Pharmacology·K KimuraH Majima
Dec 1, 1968·Proceedings of the National Academy of Sciences of the United States of America·W P Kolb, G A Granger
Nov 17, 1995·Science·T S GriffithT A Ferguson
Jan 1, 1995·The Journal of Experimental Medicine·M R AldersonD H Lynch
Aug 26, 1993·Nature·J OgasawaraS Nagata
Mar 1, 1993·Immunology Today·J J Cohen
Mar 19, 1996·Proceedings of the National Academy of Sciences of the United States of America·D L Vaux, A Strasser
May 31, 1996·The Journal of Biological Chemistry·R M PittiA Ashkenazi
Feb 1, 1997·The Journal of Clinical Investigation·P M StuartT A Ferguson
Sep 1, 1996·The Journal of Experimental Medicine·C KurtsH Kosaka
Apr 4, 1997·Science·G PanV M Dixit
Jul 7, 1997·The Journal of Experimental Medicine·S R BennettW R Heath
Oct 6, 1997·The EMBO Journal·H WalczakC T Rauch
Oct 7, 1997·The Journal of Experimental Medicine·M A Degli-EspostiC A Smith
Nov 5, 1997·The Journal of Biological Chemistry·M MacFarlaneE S Alnemri
Nov 5, 1997·Nature Genetics·G S WuW S el-Deiry
Dec 31, 1997·FEBS Letters·P SchneiderJ Tschopp
Feb 21, 1998·Current Biology : CB·S A MarstersA Ashkenazi
Feb 28, 1998·The Journal of Biological Chemistry·M MuzioV M Dixit
Jun 11, 1998·The Journal of Biological Chemistry·J G EmeryP R Young
Aug 4, 1998·European Journal of Biochemistry·K Schulze-OsthoffM E Peter
Sep 9, 1998·The Journal of Experimental Medicine·Y GaoT A Ferguson
Oct 31, 1998·Current Opinion in Immunology·T S Griffith, D H Lynch
Jan 8, 1999·Cell Stress & Chaperones·A Samali, S Orrenius
Apr 20, 1999·The Journal of Experimental Medicine·T S GriffithN A Fanger
Jul 20, 1999·The Journal of Clinical Investigation·A AshkenaziR H Schwall

❮ Previous
Next ❯

Citations

Jun 12, 2016·Cancer Immunology, Immunotherapy : CII·Poonam TewaryThomas J Sayers
Aug 11, 2016·Journal of Natural Products·Utpal K KarmakarMasami Ishibashi
May 10, 2018·Journal of Cellular Physiology·Reyhaneh Moradi MarjanehMajid Khazaei
Oct 27, 2018·Nature Reviews. Drug Discovery·Luca Cassetta, Jeffrey W Pollard
Mar 7, 2019·Bioscience Reports·Fernando J VellosoRicardo G Correa
May 31, 2019·Journal of Virology·Gaelle PicardaChris A Benedict
Jan 29, 2016·Journal of Immunology Research·Eileen Uribe-Querol, Carlos Rosales
Nov 11, 2017·Hepatology Communications·Petra HirsovaGregory J Gores
Apr 24, 2019·Mediators of Inflammation·Paulo C Carvalho-FilhoSoraya C Trindade
Dec 22, 2019·International Journal of Cancer. Journal International Du Cancer·Piotr RozgaAnna Grochot-Przeczek
Aug 7, 2019·Bioorganic & Medicinal Chemistry Letters·George Nicolae Daniel IonCostin Ioan Popescu
Apr 4, 2021·Cancers·Olivia A Diaz Arguello, Hidde J Haisma
May 17, 2021·Transplantation Reviews·Eline A van der PloegC Tji Gan
Jun 26, 2021·Journal of Experimental & Clinical Cancer Research : CR·Huanyu ZhangYi Zhang
Dec 31, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Adel NaimiSaeed Solali

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Caspases in Metabolic Diseases

Caspases, the family of cysteine proteases are involved in programmed cell death, but their role in metabolic diseases, inflammation and immunity has been of interested. Discover the latest research on caspases in metabolic diseases here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

© 2021 Meta ULC. All rights reserved